SCHEMBL4450252

SCHEMBL4450252

CNC(=O)[C@@H](NC(=O)c1ccc(C(C)C)cc1)C(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HDAC1 Q13547 3/20 0.46
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
HPGDS O60760 1/20 0.43
ROCK2 O75116 1/20 0.43
RPS6KA5 O75582 1/20 0.43
MAP4K4 O95819 1/20 0.43
CDK1 P06493 1/20 0.43
CSF1R P07333 1/20 0.43
PRKACA P17612 1/20 0.43
FLT1 P17948 1/20 0.43
RPS6KB1 P23443 1/20 0.43
CDK2 P24941 1/20 0.43
MAPK1 P28482 1/20 0.43
AKT1 P31749 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4450260 1.00 NPC1 (0.47) NPC1ALDH1A1LMNAHDAC1RAB9A
SCHEMBL4456912 0.89 KDM4E (0.55) NPC1ALDH1A1LMNA
SCHEMBL4456911 0.89 KDM4E (0.55) NPC1ALDH1A1LMNA
SCHEMBL4445027 0.87 HPGDS (0.59) NPC1ALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL4445032 0.87 HPGDS (0.59) NPC1ALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL4456906 0.86 KMT2A (0.49) NPC1ALDH1A1LMNAHDAC1SMN1; SMN2
SCHEMBL4456908 0.86 KMT2A (0.49) NPC1ALDH1A1LMNAHDAC1SMN1; SMN2
SCHEMBL4448518 0.85 L3MBTL1 (0.54) NPC1ALDH1A1LMNAHDAC1RAB9A
SCHEMBL4448522 0.85 L3MBTL1 (0.54) NPC1ALDH1A1LMNAHDAC1RAB9A
SCHEMBL4448270 0.84 ADAM17 (0.50) NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
WO-2008141446-A1 AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012010-A1 Amino acid derivatives as calcium channel blockers CACNA1G, CACNA1H, CACNA1I NPC1 2098/4885ALDH1A1 2335/4885LMNA 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.